# EDGAR Filing Document

**Accession Number:** 0001917529
**File Stem:** 0001104659-25-082644
**Filing Date:** 2025-8
**Character Count:** 8440
**Document Hash:** 79c380bee25e24c11019bacd0b9d8908
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-082644.hdr.sgml**: 20250826

**ACCESSION NUMBER**: 0001104659-25-082644

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250826

**EFFECTIVENESS DATE**: 20250826

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Atlas Venture Life Science Advisors, LLC
- **CENTRAL INDEX KEY:** 0001917529

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-22531
- **FILM NUMBER:** 251252298

**BUSINESS ADDRESS:**
- **STREET 1:** 300 TECHNOLOGY SQUARE, 8TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** (857) 201-2700

**MAIL ADDRESS:**
- **STREET 1:** 300 TECHNOLOGY SQUARE, 8TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001917529

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Atlas Venture Life Science Advisors, LLC

**Address:** 300 Technology Square, 8th Floor, Cambridge, MA 02139

**Telephone number:** 857-201-2700

**Name of agent for service:** Ommer Chohan

**Agent Address:** Atlas Venture Life Science Advisors, LLC, Cambridge, MA 02139

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-22531

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                   | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                    | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Replimune Group, Inc.            | 76029N106 | 09/04/2024     | Approval, on a non-binding advisory basis, the compensation of the company's named executive officers                                               | SECTION 14A SAY-ON-PAY VOTES |        2098300 |                0 | FOR         |                                  2098300 | FOR                         |  |
| Replimune Group, Inc.            | 76029N106 | 09/04/2024     | Approval of non-binding advisory vote on preferred frequency of future advisory votes on the compensation of the company's named executive officers | SECTION 14A SAY-ON-PAY VOTES |        2098300 |                0 | 1YR         |                                  2098300 | FOR                         |  |
| Dyne Therapeutics, Inc.          | 26818M108 | 05/30/2025     | Advisory vote on the compensation of our named executive officers                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        9130465 |                0 | FOR         |                                  9130465 | FOR                         |  |
| Dyne Therapeutics, Inc.          | 26818M108 | 05/30/2025     | Advisory vote on the frequency of future advisory votes on the compensation of our named executive officers                                         | SECTION 14A SAY-ON-PAY VOTES |        9130465 |                0 | 1YR         |                                  9130465 | FOR                         |  |
| Day One Biopharmaceuticals, Inc. | 23954D109 | 06/02/2025     | Approval on a non-binding advisory basis of the compensation of our named executive officers                                                        | SECTION 14A SAY-ON-PAY VOTES |        6430257 |                0 | FOR         |                                  6430257 | FOR                         |  |
| Generation Bio, Co.              | 37148K100 | 06/04/2025     | Advisory vote on executive compensation                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        8279484 |                0 | FOR         |                                  8279484 | FOR                         |  |
| Disc Medicine, Inc.              | 254604101 | 06/11/2025     | Advisory vote on executive compensation                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        2384456 |                0 | FOR         |                                  2384456 | FOR                         |  |
| Disc Medicine, Inc.              | 254604101 | 06/11/2025     | Advisory vote on the frequency of future executive compensation advisory votes                                                                      | SECTION 14A SAY-ON-PAY VOTES |        2384456 |                0 | 1YR         |                                  2384456 | FOR                         |  |
| Korro Bio, Inc.                  | 500946108 | 06/11/2025     | Non-binding advisory vote to approve the compensation of our named executive officers                                                               | SECTION 14A SAY-ON-PAY VOTES |        1137149 |                0 | FOR         |                                  1137149 | FOR                         |  |
| Korro Bio, Inc.                  | 500946108 | 06/11/2025     | Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of our named executive officers         | SECTION 14A SAY-ON-PAY VOTES |        1137149 |                0 | 1YR         |                                  1137149 | FOR                         |  |
| Spero Therapeutics, Inc.         | 84833T103 | 06/12/2025     | Advisory vote on approval of executive compensation as disclosed in this proxy statement                                                            | SECTION 14A SAY-ON-PAY VOTES |         305255 |                0 | FOR         |                                   305255 | FOR                         |  |
| Kymera Therapeutics, Inc.        | 501575104 | 06/25/2025     | Non-binding, advisory vote on the compensation of our named executive officers                                                                      | SECTION 14A SAY-ON-PAY VOTES |        4896462 |                0 | FOR         |                                  4896462 | FOR                         |  |
| Q32 Bio, Inc.                    | 746964105 | 06/13/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers                                                      | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | NOT VOTED   |                                        0 | NONE                        |  |
| Q32 Bio, Inc.                    | 746964105 | 06/13/2025     | To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers      | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 | NOT VOTED   |                                        0 | NONE                        |  |

## N-PX: Signature Block

**Reporting Person:** Atlas Venture Life Science Advisors, LLC

**By (Signature):** Ommer Chohan

**By (Printed Signature):** Ommer Chohan

**By (Title):** CFO

**Date:** 08/25/2025